TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02247050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment invitation
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment invitation
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment invitation
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment invitation
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment invitation
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment invitation
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
Study: NCT00522990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT9283
Description: Three weekly intravenous administration of AT9283
Study: NCT02026544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency Therapeutic Ultrasound
Description: 29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
Study: NCT00467987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgel
Description: androgel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04420624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
Study: NCT00957658

Intervention type: DEVICE
Group type: OTHER
Intervention: Accolade® TMZF® Hip Stem
Description: Accolade® TMZF® Hip Stem
Study: NCT02248506

Intervention type: OTHER
Group type: OTHER
Intervention: Clotrimazole
Description: All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
Study: NCT02754024

Intervention type: PROCEDURE
Intervention: Total shoulder arthroplasty (TSA)
Description: stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)

Intervention type: PROCEDURE
Intervention: Hemi shoulder arthroplasty (HSA)
Description: stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)

Intervention type: DEVICE
Intervention: Eclipse™ (Arthrex Inc., Naples, FL, USA)
Description: stemless humeral head implant

Intervention type: DEVICE
Intervention: Eclipse™ (Arthrex Inc., Naples, FL, USA)
Description: stemless humeral head implant
Study: NCT02299219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking Charge: Managing Cancer Online
Description: n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care and Cancer Resource Center
Description: The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments.
Study: NCT01758237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser
Description: This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser
Description: This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser Peripheral Iridotomy
Description: After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser Peripheral Iridotomy
Description: After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
Study: NCT00078533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV CTL infusion
Description: Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
Study: NCT00045916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High dosage electroconvulsive therapy
Description: Participants will receive high dosage right unilateral ECT at six times the seizure threshold.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: High dosage electroconvulsive therapy
Description: Participants will receive high dosage right unilateral ECT at six times the seizure threshold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High dosage electroconvulsive therapy
Description: Participants will receive high dosage right unilateral ECT at six times the seizure threshold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: Participants will receive nortriptyline.
Study: NCT03302377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseling & Fitbit
Description: Participants will receive individual counseling \& guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
Study: NCT00045916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: Participants will receive nortriptyline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Participants will receive venlafaxine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Participants will receive venlafaxine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Participants will receive lithium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.
Study: NCT00605917

Intervention type: DRUG
Intervention: Sertraline hydrochloride
Description: J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration.
Study: NCT03424850

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Description: * Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Description: * Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Description: * Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%
Study: NCT01998243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB), group A
Description: the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet, control group B
Description: the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diet, control group B
Description: the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
Study: NCT02605252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: peginterferon alfa-2b 80 micrograms/week for 48 weeks
Study: NCT02136303

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
Study: NCT00045916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.
Study: NCT02136303

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: S1: Dosage-dependency
Description: kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S2: Kale extract versus kale purée

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S2: Kale extract versus kale purée

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S3: Kale extract: AMD-patients
Study: NCT00045916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants will receive lithium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low dosage electroconvulsive therapy
Description: Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low dosage electroconvulsive therapy
Description: Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low dosage electroconvulsive therapy
Description: Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
Study: NCT03624140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood measurement
Description: Hemoglobin measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse co-oxymeter (SpHb)
Description: non invasive method of hemoglobin measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoCue
Description: non invasive method of hemoglobin measurement
Study: NCT04189900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
Study: NCT00424762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: 6 months of treatment of blinded study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: blinded treatment with matching placebo
Study: NCT02426320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation Interruption Protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sedation Protocol
Study: NCT04277299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IcorySolution
Description: The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
Study: NCT04056923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-printing guided
Description: 3D printed navigational template guided

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided
Description: CT-guided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: The results are shown by comparison of different colors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: The results are shown by comparison of different colors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative
Description: Preoperative localization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative
Description: Intraoperative localization.
Study: NCT03652207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isomaltulose (Palatinose(TM)
Description: isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
Study: NCT01494662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HKI-272
Description: 240 mg orally, once daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HKI-272
Description: 160 mg orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ado-Trastuzumab Emtansine
Description: 3.6 mg/kg IV every 3 weeks
Study: NCT01405924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant dimeglumine
Description: Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 RA
Description: 5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
Study: NCT02301221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin and bowel lavage
Description: An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
Study: NCT04322643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV over 30 minutes every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg IV over 30 minutes every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 800 mg IV over 60 minutes every 2 weeks
Study: NCT03665701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
Study: NCT02087644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT003
Description: Injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections
Study: NCT01651949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9vHPV Vaccine
Description: 9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
Study: NCT04437056

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cognitive nerve transfers to spastic upper extremity muscles in stroke patients
Description: Based on the fact that upper motor neuron syndrome after stroke is presented with variable clinical features, usually without affecting in the same way the entire upper extremity, we aim to investigate the efficacy of nerve transfers to spastic muscles after stroke using as donor nerves that innervate unaffected ipsilateral volitionally controlled muscles.